953 results on '"Elias, Sjoerd"'
Search Results
2. Reclassification of Appendiceal Mucinous Neoplasms and Associated Pseudomyxoma Peritonei According to the Peritoneal Surface Oncology Group International Consensus: Clinicopathological Reflections of a Two-Center Cohort Study
3. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
4. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)
5. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease
6. EGFR-targeted fluorescence molecular imaging for intraoperative margin assessment in oral cancer patients: a phase II trial
7. Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer
8. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference—a Dutch population-based study from 2008 to 2018
9. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
10. Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer
11. Harmonization of Quantitative Parenchymal Enhancement in T1 -Weighted Breast MRI.
12. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification
13. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma
14. Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging
15. Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity
16. Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy
17. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study
18. The prognostic potential of mammographic growth rate of invasive breast cancer in the Nijmegen breast cancer screening cohort.
19. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
20. Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial
21. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)
22. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers
23. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
24. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers
25. A prediction model for response to immune checkpoint inhibition in advanced melanoma
26. A prediction model for response to immune checkpoint inhibition in advanced melanoma
27. Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
28. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study
29. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study
30. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease.
31. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations
32. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease
33. Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
34. Oncological outcomes of screen-detected and non-screen-detected T1 colorectal cancers
35. A prediction model for response to immune checkpoint inhibition in advanced melanoma
36. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
37. Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
38. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
39. Development and validation of a lifestyle-based model for colorectal cancer risk prediction: the LiFeCRC score
40. Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients
41. Pedunculated Morphology of T1 Colorectal Tumors Associates With Reduced Risk of Adverse Outcome
42. Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer
43. Increased Levels of Oxidative Damage in Liver Metastases Compared with Corresponding Primary Colorectal Tumors: Association with Molecular Subtype and Prior Treatment
44. Histologic Factors Associated With Need for Surgery in Patients With Pedunculated T1 Colorectal Carcinomas
45. Triple-Negative and Non–Triple-Negative Invasive Breast Cancer: Association between MR and Fluorine 18 Fluorodeoxyglucose PET Imaging
46. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.
47. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
48. Integrating molecular nuclear imaging in clinical research to improve anticancer therapy
49. Regional Recurrence Risk Following a Negative Sentinel Node Procedure Does Not Approximate the False-Negative Rate of the Sentinel Node Procedure in Breast Cancer Patients Not Receiving Radiotherapy or Systemic Treatment
50. Discovery of common and rare genetic risk variants for colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.